New drug duo aims to tame Hard-to-Treat blood cancer

NCT ID NCT06896916

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive different dose levels, and their health will be closely monitored for side effects and disease changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam UMC, Location VUmc /ID# 267670
RECRUITING

Amsterdam, North Holland, 1081 HV, Netherlands
Austin Hospital /ID# 265984
RECRUITING

Melbourne, Victoria, 3084, Australia
Beverly Hills Cancer Center /ID# 266921
RECRUITING

Beverly Hills, California, 90211, United States
Blacktown Hospital /ID# 265983
RECRUITING

Blacktown, New South Wales, 2148, Australia
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694
RECRUITING

Tours, Indre-et-Loire, 37000, France
Chu De Lille - Hopital Claude Huriez /ID# 270193
RECRUITING

Lille, Hauts-de-France, 59037, France
Chu de Nice-Hopital Larchet Ii /Id# 266845
RECRUITING

Nice, Alpes-Maritimes, 06202, France
Colorado Blood Cancer Institute /ID# 273751
RECRUITING

Denver, Colorado, 80218, United States
Dokkyo Medical University Hospital /ID# 271648
RECRUITING

Mibu, Tochigi, 321-0293, Japan
Hôpital La Timone /ID# 267053
RECRUITING

Marseille, Bouches-du-Rhone, 13885, France
IUCT Oncopole /ID# 266391
RECRUITING

Toulouse, Occitanie, 31059, France

Contact Phone: •••-•••-••••
Jewish General Hospital /ID# 267574
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Kumamoto University Hospital /ID# 270530
RECRUITING

Kumamoto, Kumamoto, 860-8556, Japan
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282
RECRUITING

New York, New York, 10065, United States
National Cancer Center Hospital East /ID# 268343
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
Nippon Medical School Hospital /ID# 270254
RECRUITING

Bunkyo-ku, Tokyo, 113-8603, Japan
Oslo Universitetssykehus Ulleval /ID# 275433
RECRUITING

Oslo, 0450, Norway
Rutgers Cancer Institute of New Jersey /ID# 266833
RECRUITING

New Brunswick, New Jersey, 08901, United States
Sir Charles Gairdner Hospital /ID# 265985
RECRUITING

Nedlands, Western Australia, 6009, Australia
Swedish Medical Center - Seattle /ID# 268052
RECRUITING

Seattle, Washington, 98104, United States
The Alfred Hospital /ID# 265981
RECRUITING

Melbourne, Victoria, 3004, Australia
The Cancer Institute Hospital Of JFCR /ID# 268342
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
Universitair Medisch Centrum Utrecht /ID# 267660
RECRUITING

Utrecht, 3584 CX, Netherlands
University Health Network_Princess Margaret Cancer Centre /ID# 275636
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
University Of North Carolina Health Care - Hillsborough Campus /ID# 278230
RECRUITING

Hillsborough, North Carolina, 27278, United States
Washington University /ID# 266972
RECRUITING

St Louis, Missouri, 63110, United States
Wollongong Hospital /ID# 265625
RECRUITING

Wollongong, New South Wales, 2500, Australia

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA